organization · Reporting owner

Commodore Capital LP

Disclosed activity across 5 companies

Tapewire entity: 95219
SEC CIK: 0001831942

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Ambrx Biopharma Inc.AMAM · Entity 109604	10% owner	February 23, 2023	March 03, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Ambrx Biopharma Inc.

Report date February 23, 2023 · Filed March 03, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	IndirectBy Commodore Capital Master LP	35,700,000	Reported balance Holding disclosure · report date 2023-02-23 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 35,700,000 F1: The ordinary shares of the Issuer, par value $0.0001 per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares. F2: As of February 23, 2023, the Reporting Person owns 5,100,000 ADSs, representing 35,700,000 Ordinary Shares. F3: The securities are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The ordinary shares of the Issuer, par value $0.0001 per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares.

F2: As of February 23, 2023, the Reporting Person owns 5,100,000 ADSs, representing 35,700,000 Ordinary Shares.

F3: The securities are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Enliven Therapeutics, Inc.

Report date February 23, 2023 · Filed February 27, 2023

Section 16 reporting ended · disclosed 2023-02-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stock, par value $0.001 per shareSEC Table I · non-derivative	IndirectBy Commodore Capital Master LP	1,448,640	Last balance in matching sequence After 2023-02-23 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2023-02-23 · Purchase · Acquired 621.75 · Balance 718,749 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.72 to $25.28 per share, inclusive, prior to the consummation of the Merger (as defined below). The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 2 · 2023-02-23 · Other · Acquired 729,891 · Balance 1,448,640 F3: On February 23, 2023, IMARA Inc. ("IMARA") completed a merger with Enliven Therapeutics, Inc. ("Legacy Enliven"), with Legacy Enliven surviving the merger as a direct wholly owned subsidiary of IMARA (the "Merger"). Prior to the Merger, the Reporting Person was a shareholder of both IMARA and Legacy Enliven. At the effective time of the Merger, the Reporting Person's 2,473,327 shares in Legacy Enliven converted into 729,891 shares of IMARA's Common Stock. In connection with the Merger, the Reporting Person also received a dividend of one Contingent Value Right ("CVR") for or each outstanding share of IMARA's Common Stock held on February 22, 2023. Accordingly, the Reporting Person received 2,872,513 CVRs, each representing the right to receive contingent payments upon the occurrence of certain events, as set forth in the Contingent Value Rights Agreement. As a result of the Merger, the Reporting Person is no longer a 10% owner of the Issuer as of the date of this Form 4. F2: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.72 to $25.28 per share, inclusive, prior to the consummation of the Merger (as defined below). The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

F2: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F3: On February 23, 2023, IMARA Inc. ("IMARA") completed a merger with Enliven Therapeutics, Inc. ("Legacy Enliven"), with Legacy Enliven surviving the merger as a direct wholly owned subsidiary of IMARA (the "Merger"). Prior to the Merger, the Reporting Person was a shareholder of both IMARA and Legacy Enliven. At the effective time of the Merger, the Reporting Person's 2,473,327 shares in Legacy Enliven converted into 729,891 shares of IMARA's Common Stock. In connection with the Merger, the Reporting Person also received a dividend of one Contingent Value Right ("CVR") for or each outstanding share of IMARA's Common Stock held on February 22, 2023. Accordingly, the Reporting Person received 2,872,513 CVRs, each representing the right to receive contingent payments upon the occurrence of certain events, as set forth in the Contingent Value Rights Agreement. As a result of the Merger, the Reporting Person is no longer a 10% owner of the Issuer as of the date of this Form 4.

Satsuma Pharmaceuticals, Inc.

Report date November 14, 2022 · Filed November 16, 2022

Section 16 reporting ended · disclosed 2022-11-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.0001 per shareSEC Table I · non-derivative	IndirectBy Commodore Capital Master LP	461,286	Reported balance After 2022-11-14 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2022-11-14 · Sale · Disposed 3,250,000 · Balance 461,286 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.596 to $0.7997 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.596 to $0.7997 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

Vera Therapeutics, Inc.

Report date January 10, 2024 · Filed January 13, 2024

Section 16 reporting ended · disclosed 2024-01-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectBy Commodore Capital Master LP	4,400,000	Reported balance After 2024-01-10 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2024-01-10 · Sale · Disposed 1,050,000 · Balance 4,400,000 F1: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Vistagen Therapeutics, Inc.

Report date October 04, 2023 · Filed October 06, 2023

Section 16 reporting ended · disclosed 2023-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Pre-Funded Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectBy Commodore Capital Master LP	2,788,620	Reported balance After 2023-10-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-10-04 · Grant · Acquired 2,788,620 · Balance 2,788,620 F1: On October 4, 2023, Vistagen Therapeutics, Inc. (the "Issuer") closed an offering of 15,010,810 shares of its common stock, $0.001 par value per share ("Common Stock") with accompanying common warrants to purchase up to 9,294,022 shares of Common Stock (or pre-funded warrants to purchase up to 9,294,022 shares of Common Stock in lieu thereof) (the "Tranche 1 Warrants") and accompanying common warrants to purchase up to 11,265,086 shares of Common Stock (or pre-funded warrants to purchase up to 11,265,086 shares of Common Stock in lieu thereof) (the "Tranche 2 Warrants"). In lieu of shares of Common Stock, the Issuer offered pre-funded warrants to purchase up to 3,577,240 shares of Common Stock (the "Pre-Funded Warrants") with accompanying Tranche 1 Warrants and accompanying Tranche 2 Warrants. As a result of the offering and certain ownership limitations described below, Commodore Capital LP ("Commodore Capital") is no longer a 10% beneficial owner of the Issuer. F3: The Issuer offered Pre-Funded Warrants at a combined offering price of $5.379 per Pre-Funded Warrant, accompanying Tranche 1 Warrant, and accompanying Tranche 2 Warrant. F2: The Pre-Funded Warrants are exercisable from the date of issuance until fully exercised. The Pre-funded Warrants contain an exercise limitation prohibiting Commodore Capital Master LP ("Commodore Master") from exercising the Pre-Funded Warrants until such time as the holder, together with certain related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock. Due to this blocker, the Pre-funded Warrants owned by Commodore Master are not fully exercisable at this time. The blocker percentage may be increased up to 19.99% or decreased by Commodore Master upon 61 days' notice to the Issuer. F4: The securities are held directly by Commodore Master. Commodore Capital is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Tranche 1 Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.38	IndirectBy Commodore Capital Master LP	1,394,310	Reported balance After 2023-10-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-10-04 · Grant · Acquired 1,394,310 · Balance 1,394,310 F1: On October 4, 2023, Vistagen Therapeutics, Inc. (the "Issuer") closed an offering of 15,010,810 shares of its common stock, $0.001 par value per share ("Common Stock") with accompanying common warrants to purchase up to 9,294,022 shares of Common Stock (or pre-funded warrants to purchase up to 9,294,022 shares of Common Stock in lieu thereof) (the "Tranche 1 Warrants") and accompanying common warrants to purchase up to 11,265,086 shares of Common Stock (or pre-funded warrants to purchase up to 11,265,086 shares of Common Stock in lieu thereof) (the "Tranche 2 Warrants"). In lieu of shares of Common Stock, the Issuer offered pre-funded warrants to purchase up to 3,577,240 shares of Common Stock (the "Pre-Funded Warrants") with accompanying Tranche 1 Warrants and accompanying Tranche 2 Warrants. As a result of the offering and certain ownership limitations described below, Commodore Capital LP ("Commodore Capital") is no longer a 10% beneficial owner of the Issuer. F3: The Issuer offered Pre-Funded Warrants at a combined offering price of $5.379 per Pre-Funded Warrant, accompanying Tranche 1 Warrant, and accompanying Tranche 2 Warrant. F5: The Tranche 1 Warrants are exercisable from the date of issuance and expire 60 days after the later of (i) the date on which the Issuer first publicly discloses, whether by press release or Form 8-K filing, the top-line data for its PALISADE-3 study and (ii) the date on which the Issuer first publicly discloses, whether by press release or Form 8-K filing, the top-line data for its PALISADE-4 study. The Tranche 1 Warrants contain an exercise limitation prohibiting Commodore Master from exercising the Tranche 1 Warrants until such time as the holder, together with certain related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock. Due to this blocker, the Tranche 1 Warrants owned by Commodore Master are not fully exercisable at this time. The blocker percentage may be increased up to 19.99% or decreased by Commodore Master upon 61 days' notice to the Issuer. F4: The securities are held directly by Commodore Master. Commodore Capital is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Tranche 2 Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.88 · Expires 2028-10-04	IndirectBy Commodore Capital Master LP	1,690,014	Reported balance After 2023-10-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-10-04 · Grant · Acquired 1,690,014 · Balance 1,690,014 F1: On October 4, 2023, Vistagen Therapeutics, Inc. (the "Issuer") closed an offering of 15,010,810 shares of its common stock, $0.001 par value per share ("Common Stock") with accompanying common warrants to purchase up to 9,294,022 shares of Common Stock (or pre-funded warrants to purchase up to 9,294,022 shares of Common Stock in lieu thereof) (the "Tranche 1 Warrants") and accompanying common warrants to purchase up to 11,265,086 shares of Common Stock (or pre-funded warrants to purchase up to 11,265,086 shares of Common Stock in lieu thereof) (the "Tranche 2 Warrants"). In lieu of shares of Common Stock, the Issuer offered pre-funded warrants to purchase up to 3,577,240 shares of Common Stock (the "Pre-Funded Warrants") with accompanying Tranche 1 Warrants and accompanying Tranche 2 Warrants. As a result of the offering and certain ownership limitations described below, Commodore Capital LP ("Commodore Capital") is no longer a 10% beneficial owner of the Issuer. F3: The Issuer offered Pre-Funded Warrants at a combined offering price of $5.379 per Pre-Funded Warrant, accompanying Tranche 1 Warrant, and accompanying Tranche 2 Warrant. F6: The Tranche 2 Warrants are exercisable from the date of issuance and expire on October 4, 2028. The Tranche 2 Warrants contain an exercise limitation prohibiting Commodore Master from exercising the Tranche 2 Warrants until such time as the holder, together with certain related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock. Due to this blocker, the Tranche 2 Warrants owned by Commodore Master are not fully exercisable at this time. The blocker percentage may be increased up to 19.99% or decreased by Commodore Master upon 61 days' notice to the Issuer. F4: The securities are held directly by Commodore Master. Commodore Capital is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: On October 4, 2023, Vistagen Therapeutics, Inc. (the "Issuer") closed an offering of 15,010,810 shares of its common stock, $0.001 par value per share ("Common Stock") with accompanying common warrants to purchase up to 9,294,022 shares of Common Stock (or pre-funded warrants to purchase up to 9,294,022 shares of Common Stock in lieu thereof) (the "Tranche 1 Warrants") and accompanying common warrants to purchase up to 11,265,086 shares of Common Stock (or pre-funded warrants to purchase up to 11,265,086 shares of Common Stock in lieu thereof) (the "Tranche 2 Warrants"). In lieu of shares of Common Stock, the Issuer offered pre-funded warrants to purchase up to 3,577,240 shares of Common Stock (the "Pre-Funded Warrants") with accompanying Tranche 1 Warrants and accompanying Tranche 2 Warrants. As a result of the offering and certain ownership limitations described below, Commodore Capital LP ("Commodore Capital") is no longer a 10% beneficial owner of the Issuer.

F2: The Pre-Funded Warrants are exercisable from the date of issuance until fully exercised. The Pre-funded Warrants contain an exercise limitation prohibiting Commodore Capital Master LP ("Commodore Master") from exercising the Pre-Funded Warrants until such time as the holder, together with certain related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock. Due to this blocker, the Pre-funded Warrants owned by Commodore Master are not fully exercisable at this time. The blocker percentage may be increased up to 19.99% or decreased by Commodore Master upon 61 days' notice to the Issuer.

F3: The Issuer offered Pre-Funded Warrants at a combined offering price of $5.379 per Pre-Funded Warrant, accompanying Tranche 1 Warrant, and accompanying Tranche 2 Warrant.

F4: The securities are held directly by Commodore Master. Commodore Capital is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F5: The Tranche 1 Warrants are exercisable from the date of issuance and expire 60 days after the later of (i) the date on which the Issuer first publicly discloses, whether by press release or Form 8-K filing, the top-line data for its PALISADE-3 study and (ii) the date on which the Issuer first publicly discloses, whether by press release or Form 8-K filing, the top-line data for its PALISADE-4 study. The Tranche 1 Warrants contain an exercise limitation prohibiting Commodore Master from exercising the Tranche 1 Warrants until such time as the holder, together with certain related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock. Due to this blocker, the Tranche 1 Warrants owned by Commodore Master are not fully exercisable at this time. The blocker percentage may be increased up to 19.99% or decreased by Commodore Master upon 61 days' notice to the Issuer.

F6: The Tranche 2 Warrants are exercisable from the date of issuance and expire on October 4, 2028. The Tranche 2 Warrants contain an exercise limitation prohibiting Commodore Master from exercising the Tranche 2 Warrants until such time as the holder, together with certain related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock. Due to this blocker, the Tranche 2 Warrants owned by Commodore Master are not fully exercisable at this time. The blocker percentage may be increased up to 19.99% or decreased by Commodore Master upon 61 days' notice to the Issuer.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 10, 2024 Filed Jan 13, 2024 02:55 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	SaleClass A Common Stock	1,050,000	$18.00	$18,900,000.00	Disclosure SEC source: 0001493152-24-002290 · ownership.xml · nonDerivative · entry 1 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 4,400,000 F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 04, 2023 Filed Oct 6, 2023 20:05 UTC	Vistagen Therapeutics, Inc. VTGN · Entity 7955	GrantTranche 2 Warrants (Right to Buy) · Derivative	1,690,014	Not disclosed Strike: $8.88	Not disclosed	Disclosure SEC source: 0001493152-23-036497 · ownership.xml · derivative · entry 3 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 1,690,014 Underlying: Common Stock · 1,690,014 shares Expires 2028-10-04 F1 · shares: On October 4, 2023, Vistagen Therapeutics, Inc. (the "Issuer") closed an offering of 15,010,810 shares of its common stock, $0.001 par value per share ("Common Stock") with accompanying common warrants to purchase up to 9,294,022 shares of Common Stock (or pre-funded warrants to purchase up to 9,294,022 shares of Common Stock in lieu thereof) (the "Tranche 1 Warrants") and accompanying common warrants to purchase up to 11,265,086 shares of Common Stock (or pre-funded warrants to purchase up to 11,265,086 shares of Common Stock in lieu thereof) (the "Tranche 2 Warrants"). In lieu of shares of Common Stock, the Issuer offered pre-funded warrants to purchase up to 3,577,240 shares of Common Stock (the "Pre-Funded Warrants") with accompanying Tranche 1 Warrants and accompanying Tranche 2 Warrants. As a result of the offering and certain ownership limitations described below, Commodore Capital LP ("Commodore Capital") is no longer a 10% beneficial owner of the Issuer. F3 · price: The Issuer offered Pre-Funded Warrants at a combined offering price of $5.379 per Pre-Funded Warrant, accompanying Tranche 1 Warrant, and accompanying Tranche 2 Warrant. F6 · derivative.expiration_date: The Tranche 2 Warrants are exercisable from the date of issuance and expire on October 4, 2028. The Tranche 2 Warrants contain an exercise limitation prohibiting Commodore Master from exercising the Tranche 2 Warrants until such time as the holder, together with certain related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock. Due to this blocker, the Tranche 2 Warrants owned by Commodore Master are not fully exercisable at this time. The blocker percentage may be increased up to 19.99% or decreased by Commodore Master upon 61 days' notice to the Issuer. F4 · ownership.nature: The securities are held directly by Commodore Master. Commodore Capital is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 04, 2023 Filed Oct 6, 2023 20:05 UTC	Vistagen Therapeutics, Inc. VTGN · Entity 7955	GrantTranche 1 Warrants (Right to Buy) · Derivative	1,394,310	Not disclosed Strike: $5.38	Not disclosed	Disclosure SEC source: 0001493152-23-036497 · ownership.xml · derivative · entry 2 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 1,394,310 Underlying: Common Stock · 1,394,310 shares Expires not disclosed F1 · shares: On October 4, 2023, Vistagen Therapeutics, Inc. (the "Issuer") closed an offering of 15,010,810 shares of its common stock, $0.001 par value per share ("Common Stock") with accompanying common warrants to purchase up to 9,294,022 shares of Common Stock (or pre-funded warrants to purchase up to 9,294,022 shares of Common Stock in lieu thereof) (the "Tranche 1 Warrants") and accompanying common warrants to purchase up to 11,265,086 shares of Common Stock (or pre-funded warrants to purchase up to 11,265,086 shares of Common Stock in lieu thereof) (the "Tranche 2 Warrants"). In lieu of shares of Common Stock, the Issuer offered pre-funded warrants to purchase up to 3,577,240 shares of Common Stock (the "Pre-Funded Warrants") with accompanying Tranche 1 Warrants and accompanying Tranche 2 Warrants. As a result of the offering and certain ownership limitations described below, Commodore Capital LP ("Commodore Capital") is no longer a 10% beneficial owner of the Issuer. F3 · price: The Issuer offered Pre-Funded Warrants at a combined offering price of $5.379 per Pre-Funded Warrant, accompanying Tranche 1 Warrant, and accompanying Tranche 2 Warrant. F5 · derivative.expiration_date: The Tranche 1 Warrants are exercisable from the date of issuance and expire 60 days after the later of (i) the date on which the Issuer first publicly discloses, whether by press release or Form 8-K filing, the top-line data for its PALISADE-3 study and (ii) the date on which the Issuer first publicly discloses, whether by press release or Form 8-K filing, the top-line data for its PALISADE-4 study. The Tranche 1 Warrants contain an exercise limitation prohibiting Commodore Master from exercising the Tranche 1 Warrants until such time as the holder, together with certain related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock. Due to this blocker, the Tranche 1 Warrants owned by Commodore Master are not fully exercisable at this time. The blocker percentage may be increased up to 19.99% or decreased by Commodore Master upon 61 days' notice to the Issuer. F4 · ownership.nature: The securities are held directly by Commodore Master. Commodore Capital is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 04, 2023 Filed Oct 6, 2023 20:05 UTC	Vistagen Therapeutics, Inc. VTGN · Entity 7955	GrantPre-Funded Warrants (Right to Buy) · Derivative	2,788,620	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001493152-23-036497 · ownership.xml · derivative · entry 1 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 2,788,620 Underlying: Common Stock · 2,788,620 shares Expires not disclosed F1 · shares: On October 4, 2023, Vistagen Therapeutics, Inc. (the "Issuer") closed an offering of 15,010,810 shares of its common stock, $0.001 par value per share ("Common Stock") with accompanying common warrants to purchase up to 9,294,022 shares of Common Stock (or pre-funded warrants to purchase up to 9,294,022 shares of Common Stock in lieu thereof) (the "Tranche 1 Warrants") and accompanying common warrants to purchase up to 11,265,086 shares of Common Stock (or pre-funded warrants to purchase up to 11,265,086 shares of Common Stock in lieu thereof) (the "Tranche 2 Warrants"). In lieu of shares of Common Stock, the Issuer offered pre-funded warrants to purchase up to 3,577,240 shares of Common Stock (the "Pre-Funded Warrants") with accompanying Tranche 1 Warrants and accompanying Tranche 2 Warrants. As a result of the offering and certain ownership limitations described below, Commodore Capital LP ("Commodore Capital") is no longer a 10% beneficial owner of the Issuer. F3 · price: The Issuer offered Pre-Funded Warrants at a combined offering price of $5.379 per Pre-Funded Warrant, accompanying Tranche 1 Warrant, and accompanying Tranche 2 Warrant. F2 · derivative.expiration_date: The Pre-Funded Warrants are exercisable from the date of issuance until fully exercised. The Pre-funded Warrants contain an exercise limitation prohibiting Commodore Capital Master LP ("Commodore Master") from exercising the Pre-Funded Warrants until such time as the holder, together with certain related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock. Due to this blocker, the Pre-funded Warrants owned by Commodore Master are not fully exercisable at this time. The blocker percentage may be increased up to 19.99% or decreased by Commodore Master upon 61 days' notice to the Issuer. F4 · ownership.nature: The securities are held directly by Commodore Master. Commodore Capital is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
August 07, 2023 Filed Aug 9, 2023 20:10 UTC	Vistagen Therapeutics, Inc. VTGN · Entity 7955	PurchaseCommon Stock	775,756	$23.15	$17,961,078.67	Disclosure SEC source: 0001493152-23-027352 · ownership.xml · nonDerivative · entry 1 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 1,575,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.00 to $25.00 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
June 20, 2023 Filed Jun 22, 2023 20:10 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	448,217	$15.17	$6,799,003.67	Disclosure SEC source: 0001493152-23-022130 · ownership.xml · nonDerivative · entry 1 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 5,450,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.89 to $15.1904 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
February 23, 2023 Filed Feb 27, 2023 22:14 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	OtherCommon stock, par value $0.001 per share	729,891	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-23-006118 · ownership.xml · nonDerivative · entry 2 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 1,448,640 F3 · kind: On February 23, 2023, IMARA Inc. ("IMARA") completed a merger with Enliven Therapeutics, Inc. ("Legacy Enliven"), with Legacy Enliven surviving the merger as a direct wholly owned subsidiary of IMARA (the "Merger"). Prior to the Merger, the Reporting Person was a shareholder of both IMARA and Legacy Enliven. At the effective time of the Merger, the Reporting Person's 2,473,327 shares in Legacy Enliven converted into 729,891 shares of IMARA's Common Stock. In connection with the Merger, the Reporting Person also received a dividend of one Contingent Value Right ("CVR") for or each outstanding share of IMARA's Common Stock held on February 22, 2023. Accordingly, the Reporting Person received 2,872,513 CVRs, each representing the right to receive contingent payments upon the occurrence of certain events, as set forth in the Contingent Value Rights Agreement. As a result of the Merger, the Reporting Person is no longer a 10% owner of the Issuer as of the date of this Form 4. F3 · shares: On February 23, 2023, IMARA Inc. ("IMARA") completed a merger with Enliven Therapeutics, Inc. ("Legacy Enliven"), with Legacy Enliven surviving the merger as a direct wholly owned subsidiary of IMARA (the "Merger"). Prior to the Merger, the Reporting Person was a shareholder of both IMARA and Legacy Enliven. At the effective time of the Merger, the Reporting Person's 2,473,327 shares in Legacy Enliven converted into 729,891 shares of IMARA's Common Stock. In connection with the Merger, the Reporting Person also received a dividend of one Contingent Value Right ("CVR") for or each outstanding share of IMARA's Common Stock held on February 22, 2023. Accordingly, the Reporting Person received 2,872,513 CVRs, each representing the right to receive contingent payments upon the occurrence of certain events, as set forth in the Contingent Value Rights Agreement. As a result of the Merger, the Reporting Person is no longer a 10% owner of the Issuer as of the date of this Form 4. F3 · price: On February 23, 2023, IMARA Inc. ("IMARA") completed a merger with Enliven Therapeutics, Inc. ("Legacy Enliven"), with Legacy Enliven surviving the merger as a direct wholly owned subsidiary of IMARA (the "Merger"). Prior to the Merger, the Reporting Person was a shareholder of both IMARA and Legacy Enliven. At the effective time of the Merger, the Reporting Person's 2,473,327 shares in Legacy Enliven converted into 729,891 shares of IMARA's Common Stock. In connection with the Merger, the Reporting Person also received a dividend of one Contingent Value Right ("CVR") for or each outstanding share of IMARA's Common Stock held on February 22, 2023. Accordingly, the Reporting Person received 2,872,513 CVRs, each representing the right to receive contingent payments upon the occurrence of certain events, as set forth in the Contingent Value Rights Agreement. As a result of the Merger, the Reporting Person is no longer a 10% owner of the Issuer as of the date of this Form 4. F2 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
February 23, 2023 Filed Feb 27, 2023 22:14 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	PurchaseCommon stock, par value $0.001 per share	621.75	$22.07	$13,723.27	Disclosure SEC source: 0001493152-23-006118 · ownership.xml · nonDerivative · entry 1 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 718,749 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.72 to $25.28 per share, inclusive, prior to the consummation of the Merger (as defined below). The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
February 22, 2023 Filed Feb 23, 2023 21:05 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	PurchaseCommon stock, par value $0.001 per share	23,565	$5.11	$120,487.85	Disclosure SEC source: 0001493152-23-005870 · ownership.xml · nonDerivative · entry 2 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 2,872,513 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.45 to $5.64 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
February 21, 2023 Filed Feb 23, 2023 21:05 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	PurchaseCommon stock, par value $0.001 per share	8,194	$5.25	$43,010.31	Disclosure SEC source: 0001493152-23-005870 · ownership.xml · nonDerivative · entry 1 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 2,848,948 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.18 to $5.37 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
November 14, 2022 Filed Nov 16, 2022 16:05 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	SaleCommon Stock, par value $0.0001 per share	3,250,000	$0.71	$2,294,500.00	Disclosure SEC source: 0001493152-22-032622 · ownership.xml · nonDerivative · entry 1 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 461,286 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.596 to $0.7997 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
November 24, 2021 Filed Nov 29, 2021 16:30 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	PurchaseCommon Stock, par value $0.0001 per share	2,922	$5.42	$15,837.24	Disclosure SEC source: 0000905718-21-001545 · satsuma_fm4nov242021.xml · nonDerivative · entry 1 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 3,711,286 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.37 to $5.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
November 22, 2021 Filed Nov 23, 2021 16:30 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	PurchaseCommon Stock, par value $0.0001 per share	9,979	$5.49	$54,784.71	Disclosure SEC source: 0000905718-21-001523 · satsuma_fm4nov192021.xml · nonDerivative · entry 2 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 3,708,364 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.43 to $5.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
November 19, 2021 Filed Nov 23, 2021 16:30 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	PurchaseCommon Stock, par value $0.0001 per share	3,225	$5.44	$17,544.00	Disclosure SEC source: 0000905718-21-001523 · satsuma_fm4nov192021.xml · nonDerivative · entry 1 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 3,698,385 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.38 to $5.58 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
November 11, 2021 Filed Nov 12, 2021 16:31 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	PurchaseCommon Stock, par value $0.0001 per share	7,941	$6.05	$48,043.05	Disclosure SEC source: 0000905718-21-001471 · satsuma_fm4nov102021.xml · nonDerivative · entry 2 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 3,695,160 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.95 to $6.10 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
November 10, 2021 Filed Nov 12, 2021 16:31 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	PurchaseCommon Stock, par value $0.0001 per share	9,622	$5.85	$56,288.70	Disclosure SEC source: 0000905718-21-001471 · satsuma_fm4nov102021.xml · nonDerivative · entry 1 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 3,687,219 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.83 to $5.89 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
November 08, 2021 Filed Nov 10, 2021 16:30 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	PurchaseCommon Stock, par value $0.0001 per share	560	$5.99	$3,354.40	Disclosure SEC source: 0000905718-21-001460 · satsuma_fm4nov82021.xml · nonDerivative · entry 1 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 3,677,597 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.98 to $6.00 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
November 05, 2021 Filed Nov 8, 2021 16:33 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	PurchaseCommon Stock, par value $0.0001 per share	7,800	$5.95	$46,410.00	Disclosure SEC source: 0000905718-21-001450 · satsuma_fm4nov42021.xml · nonDerivative · entry 2 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 3,677,037 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.91 to $5.99 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
November 04, 2021 Filed Nov 8, 2021 16:33 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	PurchaseCommon Stock, par value $0.0001 per share	1,400	$5.88	$8,232.00	Disclosure SEC source: 0000905718-21-001450 · satsuma_fm4nov42021.xml · nonDerivative · entry 1 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 3,669,237 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.85 to $5.90 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
November 02, 2021 Filed Nov 4, 2021 16:31 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	PurchaseCommon Stock, par value $0.0001 per share	8,880	$5.64	$50,083.20	Disclosure SEC source: 0000905718-21-001430 · satsuma_fm4nov22021.xml · nonDerivative · entry 1 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 3,667,837 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.48 to $5.70 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 29, 2021 Filed Nov 2, 2021 16:30 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	PurchaseCommon Stock, par value $0.0001 per share	44,651	$5.71	$254,957.21	Disclosure SEC source: 0000905718-21-001420 · satsuma_fm4oct292021.xml · nonDerivative · entry 1 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 3,658,957 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.49 to $5.80 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 28, 2021 Filed Oct 29, 2021 16:30 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	PurchaseCommon Stock, par value $0.0001 per share	15,082	$5.55	$83,705.10	Disclosure SEC source: 0000905718-21-001408 · satsuma_fm4oct272021.xml · nonDerivative · entry 2 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 3,614,306 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.45 to $5.60 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 27, 2021 Filed Oct 29, 2021 16:30 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	PurchaseCommon Stock, par value $0.0001 per share	39,581	$5.45	$215,716.45	Disclosure SEC source: 0000905718-21-001408 · satsuma_fm4oct272021.xml · nonDerivative · entry 1 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 3,599,224 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.34 to $5.55 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 22, 2021 Filed Oct 25, 2021 16:31 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	PurchaseCommon Stock, par value $0.0001 per share	27,629	$5.51	$152,235.79	Disclosure SEC source: 0000905718-21-001391 · satsuma_fm4212021.xml · nonDerivative · entry 2 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 3,559,643 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.42 to $5.60 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 21, 2021 Filed Oct 25, 2021 16:31 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	PurchaseCommon Stock, par value $0.0001 per share	32,816	$5.40	$177,206.40	Disclosure SEC source: 0000905718-21-001391 · satsuma_fm4212021.xml · nonDerivative · entry 1 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 3,532,014 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.32 to $5.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 20, 2021 Filed Oct 21, 2021 16:30 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	PurchaseCommon Stock, par value $0.0001 per share	40,663	$5.44	$221,206.72	Disclosure SEC source: 0000905718-21-001384 · satsuma_fm4oct192021.xml · nonDerivative · entry 2 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 3,499,198 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.28 to $5.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 19, 2021 Filed Oct 21, 2021 16:30 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	PurchaseCommon Stock, par value $0.0001 per share	87,580	$5.07	$444,030.60	Disclosure SEC source: 0000905718-21-001384 · satsuma_fm4oct192021.xml · nonDerivative · entry 1 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 3,458,535 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.99 to $5.10 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 18, 2021 Filed Oct 19, 2021 17:13 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	PurchaseCommon Stock, par value $0.0001 per share	36,194	$4.87	$176,264.78	Disclosure SEC source: 0000905718-21-001373 · satsumapharm_fm4oct152021.xml · nonDerivative · entry 2 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 3,370,955 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.84 to $4.98 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 15, 2021 Filed Oct 19, 2021 17:13 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	PurchaseCommon Stock, par value $0.0001 per share	126,000	$4.83	$608,580.00	Disclosure SEC source: 0000905718-21-001373 · satsumapharm_fm4oct152021.xml · nonDerivative · entry 1 COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Commodore Capital Master LP Disclosed balance after: 3,334,761 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.75 to $4.90 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.